I
n recognition of the expanding field of precision medicine and the desire to give the right person the right medicine at the right time, the National Academies of Sciences, Engineering, and Medicine took up the task of making recommendations about molecular biomarkers. The consensus committee met throughout 2015 and released the report ''Biomarker Tests for Molecularly Targeted Therapies: Key to Unlocking Precision Medicine'' (National Academies of Sciences, Engineering, and Medicine, 2016) on March 4, 2016.
As a result of their consensus study, the committee stated 10 goals and associated recommendations. These address clinical practice, regulatory and reimbursement policy, and data challenges through the framework of a rapid learning system.
The 10 goals are as follows:
(1) Establish common evidentiary standards of clinical utility-using evidence generated both within and outside the context of clinical trials-across all stakeholders. These goals are very ambitious. I am very glad to see that they are rooted in a learning healthcare system that puts patients at the center. This system is not an easy one, and is inherently not amenable to the sort of evidence and rigor that populate the recommendations. The development of accessible, patient-centric, clinically relevant biomarkers, with the request for additional oversight and guideline development, lies in the murky interface of precision measurement and the practice of medicine. There is essentially nothing precise about human beings and their health and disease. In attempting to refine understanding of human biology to iteratively refine molecular biomarkers, and biomarkers for molecular medicine, an entire system of many actors is called on in the recommendations. This is not new territory. The proper oversight of molecular biomarkers has been hotly debated for several decades now. What this report does is to more clearly recognize the need to be more patient centric, as well as to emphatically state that this must be conducted in a rapid learning system. Now it remains to be seen whether the various actors named in the report will rise to the occasion.
